Self Efficacy, Walking Ability, Gait Speed and Physical Activity in People With Chronic Lung Disease

NCT01583595 | Completed

• 1 other identifier: 11-008157
• Study Type: observational
• Target: 70
• Locations: 1 country
• Sites: 1

Brief Summary

Most patients with chronic lung disease underestimate their actual walking ability due to low confidence. To better understand the relationships between lung function, self-efficacy for walking (confidence in ability to walk a defined distance), actual walking ability for the same distance gait speed and physical activity level-PAL- (total energy expenditure/resting metabolic rate). Quality of life, self efficacy for activity questionnaires, physical activity level measurement, 4-meter gait speed and 6-minute walk distance will be measured.

Conditions

Chronic Lung Disease; Self-efficacy

Keywords

Chronic Lung Disease; Exercise; Self-efficacy

Outcome Measures

Primary Outcomes (1)

• Analyze associations between self-efficacy for walking, gait speed, physical activity level and perceptions of symptoms in patient with chronic lung disease (COPD and Pulmonary Fibrosis)

  Correlation , regression models and mediation analysis (self efficacy and physical activity) will be performed.

  Day of enrollment.

Secondary Outcomes (1)

• Predictive utility of 4-meter gait speed for estimating physical activity level (PAL) as validated by gold standard activity monitor.

  1 week

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults with chronic lung disease

You may qualify if:

• Men and women 40 years and older
• Diagnosis of any chronic lung disease as evidenced by pulmonary function testing completed within the prior 12 months
• Able to walk independently and successfully complete the 6-minute walk assessment

You may not qualify if:

• Unable to walk without assistance or complete the 6-minute walk assessment
• Patients unable to comprehend and accurately respond to the study questionnaires either by written or spoken communication
• Patients diagnosed with or treated for a lower respiratory tract infection or COPD exacerbation within the prior 30 days

Sponsors & Collaborators

• Mayo Clinic: lead

Study Sites (1)

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location

MeSH Terms

Conditions

Motor Activity

Condition Hierarchy (Ancestors)

Behavior

Study Officials

• Roberto P Benzo, M.D., MSc

  Mayo Clinic

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Consultant Pulmonary and Critical Care Medicine

Study Record Dates

• First Submitted: February 7, 2012
• First Posted: April 24, 2012
• Study Start: December 1, 2011
• Primary Completion: July 1, 2012
• Study Completion: July 1, 2012
• Last Updated: April 4, 2013

Record last verified: 2013-03

Locations

US (1)